Abstracts describing the recent clinical experience of ONC201 across various solid tumors will be presented at the 2017 American Society of Clinical Oncology (ASCO) annual meeting.
The first, “Clinical activity of the selective DRD2 antagonist ONC201, an imipridone, in metastatic endometrial cancer (mEC)” will be presented in the session Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics on Saturday June 3, 1:15 PM to 4:45 PM in Hall A
This abstract describes the clinical experience of five patients with metastatic endometrial cancer, treated on a weekly or every three week schedule. Two patients exhibited regressions of individual metastatic lesions, and one patient experienced stable disease for 42 weeks.
The second, “Anticancer and immunostimulatory activity of the imipridone ONC201, a selective DRD2 antagonist, in advanced cancer patients” will be presented in the session Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics on Monday June 5, 8:00 AM to 11:30 AM in Hall A.
This abstract describes safety and efficacy profile seen in patients treated with ONC201 on a weekly schedule, and the immune stimulation effects of ONC201, preclinically and clinically. Preclinically, ONC201 showed stimulatory effects on immune cells including increased intratumoral NK cell infiltration in xenografts. In patients, ONC201 exhibited sustained and late anti-cancer activity, and increased circulating NK cells by 2-10 fold.